Seite 3 – CureVac

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity

19. Juli 2016Clinical Data,Mechanism of Action,Prophylactic Vaccines

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs

23. Juni 2016Mechanism of Action,Prophylactic Vaccines

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

16. Juni 2016Clinical Data,Oncology

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile

15. Juli 2015Oncology,RNA Immunomodulator,Most Referenced Publications

Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals

30. Juni 2015Mechanism of Action,Natural mRNA,Most Referenced Publications

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer

1. Januar 2015Clinical Data,Review Articles,Oncology

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors

15. August 2014Mechanism of Action,Oncology

A development, that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs

6. November 2013Review Articles,Natural mRNA,Prophylactic Vaccines

The regulatory landscape for actively personalized cancer immunotherapies

31. Oktober 2013Oncology

A novel, disruptive vaccination technology, Self-adjuvanted RNActive® vaccines

4. Oktober 2013Review Articles,Prophylactic Vaccines